UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 1 April 2026, London UK
GSK, Pfizer and Shionogi complete changes to ViiV Healthcare
shareholding
●
Completion of Pfizer's exit of
its investment in ViiV Healthcare
●
Increase of
Shionogi's holding to 21.7%, with GSK maintaining 78.3% majority
share
GSK plc (LSE/NYSE: GSK) ("GSK"), and Shionogi & Co., Ltd (Head
Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi,
Ph.D) ("Shionogi"), further to their announcements on 20 January
2026, announce the completion of the transaction for the 11.7%
economic interest in ViiV Healthcare Limited ("ViiV Healthcare")
previously held by Pfizer Inc. (NYSE: PFE) ("Pfizer") to be
replaced with an investment by Shionogi. As a result of this
transaction, Shionogi has increased its economic interest in ViiV
Healthcare to 21.7%. GSK maintains its 78.3% majority owned
economic interest.
ViiV Healthcare issued new shares to Shionogi for consideration of
$2.125 bn and cancelled Pfizer's holding in ViiV Healthcare. Pfizer
received $1.875 bn and GSK received a special dividend of $0.250 bn
(paid in GBP).
Financial Considerations
The
Pfizer put option liability shown in GSK's accounts for the year
ended 31 December 2025 was extinguished through retained earnings
at completion. The put option liability was remeasured immediately
prior to completion on the same methodology as at 31 December 2025,
with the fair value change in the liability recognised as an
adjusting item through other operating income.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
About Shionogi
Shionogi & Co., Ltd. is a leading global research-driven
pharmaceutical company dedicated to bringing benefits to patients
based on its corporate philosophy of "supplying the best possible
medicine to protect the health and well-being of the patients we
serve." Shionogi has discovered and developed novel antibiotics,
medicines for HIV and influenza, and currently markets medicines
for infectious diseases and central nervous system disorders. For
more information, visit https://www.shionogi.com/global/en.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in
November 2009 dedicated to delivering advances in treatment and
care for people living with HIV and for people who could benefit
from HIV prevention. The company's aims are to take a deeper and
broader interest in HIV and AIDS than any company has done before
and take a new approach to deliver effective and innovative
medicines for HIV treatment and prevention, as well as support
communities affected by HIV.
For more information on the company, its management, portfolio,
pipeline, and commitment, please visit viivhealthcare.com.
Forward-Looking Statements
This announcement contains forward-looking statements. These
statements are based on expectations in light of the information
currently available and assumptions that are subject to risks and
uncertainties which could cause actual results to differ materially
from these statements. These risks and uncertainties particularly
apply with respect to transaction-related forward-looking
statements. GSK and Shionogi disclaim any intention or obligation
to update or revise any forward-looking statements whether as a
result of new information, future events or otherwise.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Sarah Clements
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Alison Hunt
|
+1 540 742 3391
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Constantin Fest
|
+44 (0) 7831 826525
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Sam Piper
|
+44 (0) 7824 525779
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
Shionogi enquiries
Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for
2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
01, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|